The effects of four ribonucleic acid virus inhibitors were evaluated in cell cultures and in mice to determine inhibitory effects against bluetongue virus and Colorado tick fever virus (CTFV). Test compounds included 1-/-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin), 3-deazaguanine, 3-deazauridine, and 9-(S)-(2,3-dihydroxypropyl)adenine. Ribavirin-2',3',5'-triacetate (ribavirin triacetate) was evaluated in vivo against CTFV. Inhibition of cytopathic effect and plaque reduction were used to evaluate antiviral activity. In cytopathic effect inhibition studies, bluetongue virus was markedly inhibited by 3-deazaguanine and 3-deazauridine in Vero cells with moderate inhibition by the other agents. Ribavirin and 3-deazaguanine markedly inhibited CTFV in MA-104 cells, 3-deazauridine was slightly less active, and 9-(S)-(2,3-dihydroxypropyl)adenine was negative. Ribavirin was less effective in Vero cells against CTFV. When mice were inoculated intracerebrally with CTFV and treated by a single intracerebral injection with drug, ribavirin triacetate increased the number of survivors, 3-deazaguanine increased mean survival time, and ribavirin was negative. Intraperitoneal treatment of infected mice with ribavirin triacetate for 1 week significantly increased the number of survivors and mean survival time, providing strong evidence that the agent is active across the blood-brain barrier.
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Bluetongue virus (BTV) and Colorado tick fever virus (CTFV) are members of the family Reoviridae, a group of viruses whose genomes consist of 10 to 12 segments of double-stranded ribonucleic acid (RNA) (11) . These two and other related viruses were recently classified into a separate taxonomic group, the orbivirus genus (4) . A large number of the orbiviruses isolated to date are insect viruses, and most isolates are nonpathogenic to humans and domestic animals (6, 8, 28) .
The most important orbivirus pathogen of veterinary medical concern is BTV, which causes serious disease in sheep, cattle, and goats (28) . The most pronounced effects seen with BTV are congenital malformations in lambs and calves (3, 15).
CTFV causes a febrile disease in humans that is usually not fatal. Chills, fever, headaches, muscle soreness, and vomiting are associated with the illness (2) , and encephalitis may occur in children. Teratogenic effects (7) and encephalitis (13) have been induced by the virus in experimentally infected mice.
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The effects of antiviral agents on infections caused by members of the orbivirus group have yet to be determined. The purpose of this study was to establish parameters for such evaluations and to determine the effect of some known inhibitors of other RNA viruses on these orbiviruses. Of the compounds selected for evaluation, 1-/8-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) has been the most thoroughly investigated against other viruses (22, 23) . It has a broad spectrum of activity against deoxyribonucleic acid (DNA) and RNA viruses. 3-Deazaguanine (3-DG) and 9-(S)-(2,3-dihydroxypropyl)adenine [(S)-DHPA] also inhibit both DNA and RNA viruses (1, 5), whereas 3-deazauridine (3-DU) is primarily an RNA virus inhibitor (12, 18 (25) and arenaviruses (24 (26) at -90°C. Since an objective of this research was to determine the response of various members of the Reot'iridae family of viruses to these antiviral substances, we had some concern about whether BTV was indeed similar to CTFV, although both have been provisionally placed in the orbivirus group. To further investigate the relationship of these two viruses, viral genomic RNAs were extracted from virions (27) and electrophoresed into 10% polyacrylamide gels prepared by the method of Laemmli (14) . Reovirus type 3 (Abney strain) was run in parallel for comparison. The identity of CTFV was further established by serum neutralization with anti-CTFV hamster serum. The anti-CTFV serum and reovirus were obtained from the Viral and Rickettsial Disease Laboratory, California State Department of Public Health, Berkeley.
In vitro antiviral experiments. The methods used to assess antiviral activity included inhibition of viral cytopathic effect (CPE) and plaque reduction. The CPE studies were conducted in 96-well disposable microplates (Vangard International, Neptune, N.J.) by the method of Sidwell and Huffman (21 compound did reduce plaque sizes by 50% at a dose of 1,000 yug/ml.
In the mouse studies with CTFV, in which the drug was administered i.c. (Table 3) , ribavirin had no appreciable effect on the infection. The 15-mg/kg dose appeared to be moderately toxic, with deaths noted in toxicity control mice. Treatment with 3-DG significantly increased mean survival time at both doses used when administered 3 h before the virus. An increase in the number of survivors was observed for the group of mice treated i.c. with 15 mg of ribavirin triacetate per kg 3 h before virus inoculation. When ribavirin triacetate was given intraperitoneally for 7 days to infected mice (Table 4) , statistically significant survivor and mean survival time increases were evident. The drug appeared to be well tolerated at these high concentrations, although no weight gains were evident in toxicity control mice until 3 to 4 days after treatment ended.
DISCUSSION
In the cell culture studies reported here, all four agents had moderate to marked inhibitory effects against BTV, with 3-DG and 3-DU being most active. Only (S)-DHPA was of no apparent value in reducing CTFV CPE; the other agents were very active inhibitors. There appeared to be definite cell-related differences in antiviral effects of ribavirin against CTFV in MA-104 (Table 1) "Hours before and after infecting with virus. Probability (chi-square analysis with Yate's correction). Probability (Student t test). "Of 14, 9 died within 1 h due to drug toxicity. Of 14, 7 died within 1 h due to drug toxicity.
in this cell line. It was particularly interesting that ribavirin was ineffective against CTFV-induced CPE in Vero cells, although the drug was actually antiviral when assayed by plaque reduction. Development of CTFV CPE was relatively slow (4.5 days to reach 100%) and was not easily discernible, which may partially explain this variation in results. The CPE assay also required a 10-fold greater virus concentration to cause the CPE than was required in MA-104 18. termining cytotoxicity in MA-104 cells revealed that each drug inhibits uptake and incorporation of tH-labeled amino acids, uridine, or thymidine (23a). Although implying a lack of specificity of antiviral action, these data may not correlate directly to toxic effects of drug in vivo. Ribavirin and (S)-DHPA appear to be well tolerated in animals (5, 23), whereas 3-DG and 3-DU have relatively greater toxic properties in vivo (1, 17).
It is not unusual that these two provisional members of the orbivirus genus of viruses responded somewhat differently to these drugs, since the comparative RNA banding patterns run indicated that the CTFV had 12, rather than the usual 10, double-stranded RNA segments. To our knowledge, this is the first published report of RNA banding patterns run with CTFV, and the results suggest that further consideration should be given as to the appropriate classification of this virus.
Conditions of the in vivo studies were designed, in part, to evaluate the ability of ribavirin triacetate to cross the blood-brain barrier and to evaluate the other positive agents i.c. (S)-DHPA, which may also have the potential of crossing the blood-brain barrier, was inactive against the virus in vitro, so it was not evaluated in vivo. Sufficient quantities of 3-DU were not available to test that compound in vivo. Ribavirin and 3-DG were previously shown to be ineffective against central nervous system infections unless given i.c. (1, 20) .
It is believed that the increase in mean survival time caused by 3-I)G may be due to the drug persisting in the brain for a long period of time. The compound is relatively water insoluble (1) and therefore was administered as a particulate suspension. Treatment of infected mice with ribavirin triacetate caused a marginally significant increase in the number of survivors when the compound was given i.c. This effect may be due, in part, to a slow clearance of drug from the injection site and the persistence of the compound in the blood (19 Results of these studies provide further evidence of the usefulness of ribavirin triacetate in treating certain viral infections. Additional research will be required to determine whether the agent is efficacious against other virus-induced encephalitis diseases when the drug is administered other than i.c. 
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